Cambrian Biopharma Closes $100 Million Series C To Advance Healthspan-Boosting Therapeutics To The Clinic
Amount Raised
$100 Million
Round Type
Series C
New YorkBiotechnologyHealthcareDescription
Cambrian Biopharma, a multi-asset longevity biotech, today announced the close of an oversubscribed Series C financing, which raised $100 million. The financing was co-led by Anthos Capital and SALT Fund, with participation from existing investors Apeiron Investment Group, Future Ventures, Moore Capital and others, to develop therapeutics to combat the biological drivers of aging, treat and prevent age-related diseases and lengthen healthspan. With this financing, Cambrian has raised approximately $160 million since the company was founded in 2019.
Quick answer
Cambrian BioPharma raised $100 Million in a Series C round, dated October 26, 2021. Cambrian BioPharma is based in New York, New York, United States.
- How much did Cambrian BioPharma raise?
- Cambrian BioPharma raised $100 Million in a Series C round on October 26, 2021.
- What does Cambrian BioPharma do?
- Cambrian Biopharma is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.
- Where is Cambrian BioPharma based and how big is it?
- Cambrian BioPharma is based in New York, New York, United States. Fundz records about 30 employees.
- Who are the decision-makers at Cambrian BioPharma?
- Fundz holds 1 contact at Cambrian BioPharma, including the Executive Officer, Director, Promoter. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Biotechnology around the same time
Companies in the same sectors as Cambrian BioPharma that raised within 45 days of this round, from Fundz verified event records.
- SpineThera, Inc. raised $1.2M (Seed) on December 10, 2021.
- Biofrontera raised $15M on December 10, 2021.
- iSpecimen raised $21M on December 9, 2021.
- PetDx, Inc. raised $62M (Series B) on December 9, 2021.
- AEON Biopharma raised $30M on December 8, 2021.
- Pasithea Therapeutics Corp. raised $30M on December 7, 2021.
Who to call at Cambrian BioPharma, and when
A new round usually means Cambrian BioPharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Cambrian BioPharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Cambrian BioPharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Cambrian BioPharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Cambrian BioPharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Cambrian BioPharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.